Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-744 by AbbVie for Myelofibrosis: Likelihood of Approval
ABBV-744 is under clinical development by AbbVie and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...
ABBV-744 by AbbVie for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
ABBV-744 is under clinical development by AbbVie and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...
ABBV-744 by AbbVie for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
ABBV-744 is under clinical development by AbbVie and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...